Literature DB >> 11029795

Interleukin-4 and breast cancer.

S Nagai1, M Toi.   

Abstract

IL-4 is a pleiotropic cytokine produced by T lymphocytes which acts on various cells of such as T and B lymphocytes, monocytes, fibroblast, endothelial cells, macrophages and some others. IL-4 was originally described as a B cell growth factor, and now known to provide potent anti-tumor activity against various tumors, including breast cancer. IL-4 can induce apoptosis in cultured breast cancer cells. In addition, it has been clarified that IL-4 plays an important role in the regulation of estrogen synthesis enzymes including 17beta-HSD and 3beta-HSD. These findings imply that IL-4 is a key enzyme not only for Th2 type immune reactions but also for tumor cell growth itself in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029795     DOI: 10.1007/bf02967457

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  17 in total

Review 1.  Leukocytes in mammary development and cancer.

Authors:  Lisa M Coussens; Jeffrey W Pollard
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

2.  The Influence of Biomaterials on Cytokine Production in 3D Cultures.

Authors:  Mary C Regier; Sara I Montanez-Sauri; Michael P Schwartz; William L Murphy; David J Beebe; Kyung Eun Sung
Journal:  Biomacromolecules       Date:  2017-02-16       Impact factor: 6.988

3.  Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.

Authors:  Marilyn Fernandez; Mercedes Porosnicu; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  IL-4, JAK-STAT signaling, and pain.

Authors:  Melanie Busch-Dienstfertig; Sara González-Rodríguez
Journal:  JAKSTAT       Date:  2014-01-02

5.  Association between lysyl oxidase and fibrotic focus in relation with inflammation in breast cancer.

Authors:  Young Ju Jeong; Sung Hwan Park; Sung Hee Mun; Sang Gyu Kwak; Sun-Jae Lee; Hoon Kyu Oh
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

6.  Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers.

Authors:  Chi-Chen Hong; Song Yao; Susan E McCann; Ree Y Dolnick; Paul K Wallace; Zhihong Gong; Lei Quan; Kelvin P Lee; Sharon S Evans; Elizabeth A Repasky; Stephen B Edge; Christine B Ambrosone
Journal:  Breast Cancer Res Treat       Date:  2013-04-30       Impact factor: 4.872

7.  The concurrent effects of azurin and Mammaglobin-A genes in inhibition of breast cancer progression and immune system stimulation in cancerous BALB/c mice.

Authors:  Payam Ghasemi-Dehkordi; Abbas Doosti; Mohammad-Saeid Jami
Journal:  3 Biotech       Date:  2019-06-18       Impact factor: 2.406

8.  Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.

Authors:  Anjana Kumari Negi; Archana Bhatnagar; Navneet Agnihotri
Journal:  Inflammopharmacology       Date:  2016-01-09       Impact factor: 4.473

9.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

Authors:  David G DeNardo; Jairo B Barreto; Pauline Andreu; Lesley Vasquez; David Tawfik; Nikita Kolhatkar; Lisa M Coussens
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

Review 10.  Leptin-cytokine crosstalk in breast cancer.

Authors:  Gale Newman; Ruben Rene Gonzalez-Perez
Journal:  Mol Cell Endocrinol       Date:  2013-04-04       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.